EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Generation of Allogeneic CAR ‐T Circumvents Functional Deficits in Patient‐Derived Autologous Product for Glioblastoma

Sabra K Salim, Muhammad Vaseem Shaikh, Jeffrey Wei, William T Maich, Alisha Anand, Oliver Y Tang, Minomi K Subapanditha, Zahra Alizada, Yujin Suk, Manoj Singh, Kui Zhai, Aapti Khanna und 11 weitere

International Journal of Cancer · 15.09.2026 · 159 (6) · 1521-1534

DOI: 10.1002/ijc.70509 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Cancer, online erschienen am 24.04.2026. Verfasst von Sabra K Salim und 22 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry and Biomedical Sciences, McMaster University, Hamilton, Ontario, Canada. Hauptthemen laut MEDLINE: Glioblastoma, Immunotherapy, Adoptive, Brain Neoplasms, Receptors, Chimeric Antigen. Die Arbeit nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Genome Canada.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Glioblastoma (GBM) is the most common malignant brain tumor in adults, with a poor prognosis despite aggressive standard of care. Chimeric antigen receptor T‐cell (CAR‐T) therapy has shown promising results in liquid malignancies, but clinical trials in GBM targeting various tumor antigens have not shown durable clinical benefit. While this may be attributable to various tumor‐intrinsic immune evasion strategies characteristic of GBM, little work has been done to assess whether the issue is due to the quality of the CAR‐T treatment itself. Currently, CAR‐Ts for GBMs and liquid malignancies are manufactured in an autologous setting in which T‐cells are extracted from patients, engineered ex vivo, and subsequently reinfused back. However, peripheral T‐cells taken from untreated GBM patients have demonstrated qualitative and functional deficits, which may contribute to suboptimal treatment outcomes. Thus, we aimed to establish whether CAR‐Ts generated from GBM patients would show reduced efficacy in comparison to healthy donors using our previously validated CD133 CAR‐T. In this work, we show pre‐treatment exhaustion and reduced survival advantage in autologous, patient‐derived CD133‐targeting CAR‐T cell products using an orthotopic xenograft model of human GBM. To overcome the functional and logistical considerations of autologous therapy, we additionally aimed to generate an “off‐the‐shelf” allogeneic CD133 CAR‐T. Using CRISPR gene editing technology, we generated TCR‐knockout CAR‐T cells with comparable pre‐clinical efficacy to our autologous models. Ultimately, this work highlights the need to reassess autologous CAR‐T therapy for GBM and consider allogeneic approaches as biologically informed therapeutic alternatives.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlioblastomaImmunotherapy, AdoptiveBrain NeoplasmsReceptors, Chimeric AntigenT-LymphocytesHumansAnimalsMiceXenograft Model Antitumor AssaysAC133 AntigenTransplantation, AutologousFemaleT-Cell Exhaustion

Stichwörter der Autor:innen

CAR‐TGBMallogeneicautologousimmunotherapy

Substanzen

Receptors, Chimeric AntigenAC133 AntigenPROM1 protein, human

Autor:innen und Institutionen

  • Department of Biochemistry and Biomedical Sciences, McMaster University, Hamilton, Ontario, Canada.
  • Department of Surgery, McMaster University, Hamilton, Ontario, Canada.
  • Department of Molecular Genetics, University of Toronto, Toronto, Ontario, Canada.
  • Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
  • McMaster Immunology Research Centre, McMaster University, Hamilton, Ontario, Canada.
  • Genetics and Genome Biology, Hospital for Sick Children, Toronto, Ontario, Canada.

ORCID-Profile: Sheila K Singh

Förderung

  • Genome Canada

Zitieren

APA

Salim, S. K., Shaikh, M. V., Wei, J., Maich, W. T., Anand, A., Tang, O. Y., Subapanditha, M. K., Alizada, Z., Suk, Y., Singh, M., Zhai, K., Khanna, A., Brakel, B., Dimitrov, V., Tabunshchyk, Z., Chan, K., Brown, K. R., Vora, P., O'Rourke, D. M., …, & Singh, S. K. (2026). Generation of Allogeneic CAR ‐T Circumvents Functional Deficits in Patient‐Derived Autologous Product for Glioblastoma. International Journal of Cancer, 159(6), 1521-1534. https://doi.org/10.1002/ijc.70509

Vancouver

Salim SK, Shaikh MV, Wei J, Maich WT, Anand A, Tang OY, et al. Generation of Allogeneic CAR ‐T Circumvents Functional Deficits in Patient‐Derived Autologous Product for Glioblastoma. International Journal of Cancer. 2026;159(6):1521-1534. doi:10.1002/ijc.70509

BibTeX
@article{Salim2026,
  author = {Salim, Sabra K and Shaikh, Muhammad Vaseem and Wei, Jeffrey and Maich, William T and Anand, Alisha and Tang, Oliver Y and Subapanditha, Minomi K and Alizada, Zahra and Suk, Yujin and Singh, Manoj and Zhai, Kui and Khanna, Aapti and Brakel, Benjamin and Dimitrov, Vassil and Tabunshchyk, Zoya and Chan, Katie and Brown, Kevin R and Vora, Parvez and O'Rourke, Donald M and Binder, Zev A and Venugopal, Chitra and Moffat, Jason and Singh, Sheila K},
  title = {Generation of Allogeneic CAR ‐T Circumvents Functional Deficits in Patient‐Derived Autologous Product for Glioblastoma},
  journal = {International Journal of Cancer},
  year = {2026},
  volume = {159},
  number = {6},
  pages = {1521--1534},
  doi = {10.1002/ijc.70509}
}
Kostenlos starten →